 | • レポートコード：MRC2-11QY07619 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は異染性白質ジストロフィー（MLD）治療のグローバル市場について調査・分析したレポートです。種類別（AGT-183、DUOC-01、GSK-2696274、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別異染性白質ジストロフィー（MLD）治療の競争状況、市場シェア ・世界の異染性白質ジストロフィー（MLD）治療市場：種類別市場規模 2015年-2020年（AGT-183、DUOC-01、GSK-2696274、その他） ・世界の異染性白質ジストロフィー（MLD）治療市場：種類別市場規模予測 2021年-2026年（AGT-183、DUOC-01、GSK-2696274、その他） ・世界の異染性白質ジストロフィー（MLD）治療市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の異染性白質ジストロフィー（MLD）治療市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の異染性白質ジストロフィー（MLD）治療市場分析：米国、カナダ ・ヨーロッパの異染性白質ジストロフィー（MLD）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの異染性白質ジストロフィー（MLD）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の異染性白質ジストロフィー（MLD）治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの異染性白質ジストロフィー（MLD）治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：ArmaGen Inc、GlaxoSmithKline Plc、Recursion Pharmaceuticals Inc、RegenxBio Inc、Takeda ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Metachromatic Leukodystrophy (MLD) Treatment Market
The global Metachromatic Leukodystrophy (MLD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Metachromatic Leukodystrophy (MLD) Treatment Scope and Market Size
Metachromatic Leukodystrophy (MLD) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metachromatic Leukodystrophy (MLD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Metachromatic Leukodystrophy (MLD) Treatment market is segmented into
AGT-183
DUOC-01
GSK-2696274
Others
Segment by Application, the Metachromatic Leukodystrophy (MLD) Treatment market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Metachromatic Leukodystrophy (MLD) Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Metachromatic Leukodystrophy (MLD) Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Metachromatic Leukodystrophy (MLD) Treatment Market Share Analysis
Metachromatic Leukodystrophy (MLD) Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Metachromatic Leukodystrophy (MLD) Treatment business, the date to enter into the Metachromatic Leukodystrophy (MLD) Treatment market, Metachromatic Leukodystrophy (MLD) Treatment product introduction, recent developments, etc.
The major vendors covered:
ArmaGen Inc
GlaxoSmithKline Plc
Recursion Pharmaceuticals Inc
RegenxBio Inc
Takeda
…
1 Study Coverage
1.1 Metachromatic Leukodystrophy (MLD) Treatment Product Introduction
1.2 Market Segments
1.3 Key Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type
1.4.2 AGT-183
1.4.3 DUOC-01
1.4.4 GSK-2696274
1.4.5 Others
1.5 Market by Application
1.5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size, Estimates and Forecasts
2.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue 2015-2026
2.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales 2015-2026
2.2 Global Metachromatic Leukodystrophy (MLD) Treatment, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Metachromatic Leukodystrophy (MLD) Treatment Competitor Landscape by Players
3.1 Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
3.1.1 Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers (2015-2020)
3.1.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2015-2020)
3.2 Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers
3.2.1 Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2015-2020)
3.2.2 Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy (MLD) Treatment Revenue in 2019
3.2.5 Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Metachromatic Leukodystrophy (MLD) Treatment Price by Manufacturers
3.4 Metachromatic Leukodystrophy (MLD) Treatment Manufacturing Base Distribution, Product Types
3.4.1 Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Metachromatic Leukodystrophy (MLD) Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Metachromatic Leukodystrophy (MLD) Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type (2015-2020)
4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020)
4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2015-2020)
4.1.3 Metachromatic Leukodystrophy (MLD) Treatment Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Type (2021-2026)
4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Type (2021-2026)
4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Type (2021-2026)
4.2.3 Metachromatic Leukodystrophy (MLD) Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application (2015-2020)
5.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020)
5.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2015-2020)
5.1.3 Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2015-2020)
5.2 Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Application (2021-2026)
5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Application (2021-2026)
5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Application (2021-2026)
5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Application (2021-2026)
6 North America
6.1 North America Metachromatic Leukodystrophy (MLD) Treatment by Country
6.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
6.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Type
6.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Application
7 Europe
7.1 Europe Metachromatic Leukodystrophy (MLD) Treatment by Country
7.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
7.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Type
7.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment by Region
8.1.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region
8.1.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Type
8.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Application
9 Latin America
9.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment by Country
9.1.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
9.1.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Type
9.3 Central & South America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment by Country
10.1.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
10.1.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Type
10.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Application
11 Company Profiles
11.1 ArmaGen Inc
11.1.1 ArmaGen Inc Corporation Information
11.1.2 ArmaGen Inc Description and Business Overview
11.1.3 ArmaGen Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.1.5 ArmaGen Inc Related Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Corporation Information
11.2.2 GlaxoSmithKline Plc Description and Business Overview
11.2.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.2.5 GlaxoSmithKline Plc Related Developments
11.3 Recursion Pharmaceuticals Inc
11.3.1 Recursion Pharmaceuticals Inc Corporation Information
11.3.2 Recursion Pharmaceuticals Inc Description and Business Overview
11.3.3 Recursion Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.3.5 Recursion Pharmaceuticals Inc Related Developments
11.4 RegenxBio Inc
11.4.1 RegenxBio Inc Corporation Information
11.4.2 RegenxBio Inc Description and Business Overview
11.4.3 RegenxBio Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.4.5 RegenxBio Inc Related Developments
11.5 Takeda
11.5.1 Takeda Corporation Information
11.5.2 Takeda Description and Business Overview
11.5.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.5.5 Takeda Related Developments
11.1 ArmaGen Inc
11.1.1 ArmaGen Inc Corporation Information
11.1.2 ArmaGen Inc Description and Business Overview
11.1.3 ArmaGen Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Products Offered
11.1.5 ArmaGen Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Metachromatic Leukodystrophy (MLD) Treatment Market Estimates and Projections by Region
12.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Regions 2021-2026
12.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Regions 2021-2026
12.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast (2021-2026)
12.2.1 North America: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast (2021-2026)
12.2.2 North America: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast (2021-2026)
12.2.3 North America: Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2021-2026)
12.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast (2021-2026)
12.3.1 Europe: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast (2021-2026)
12.3.2 Europe: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast (2021-2026)
12.3.3 Europe: Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Region (2021-2026)
12.5 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast (2021-2026)
12.5.1 Latin America: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast (2021-2026)
12.5.2 Latin America: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast (2021-2026)
12.5.3 Latin America: Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Metachromatic Leukodystrophy (MLD) Treatment Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Metachromatic Leukodystrophy (MLD) Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Metachromatic Leukodystrophy (MLD) Treatment Market Segments
Table 2. Ranking of Global Top Metachromatic Leukodystrophy (MLD) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AGT-183
Table 5. Major Manufacturers of DUOC-01
Table 6. Major Manufacturers of GSK-2696274
Table 7. Major Manufacturers of Others
Table 8. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Regions (2015-2020)
Table 12. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Manufacturers (2015-2020)
Table 15. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Metachromatic Leukodystrophy (MLD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metachromatic Leukodystrophy (MLD) Treatment as of 2019)
Table 17. Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Metachromatic Leukodystrophy (MLD) Treatment Price (2015-2020) (USD/Pcs)
Table 20. Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Metachromatic Leukodystrophy (MLD) Treatment Product Type
Table 22. Date of International Manufacturers Enter into Metachromatic Leukodystrophy (MLD) Treatment Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 25. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2015-2020)
Table 26. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2015-2020)
Table 28. Metachromatic Leukodystrophy (MLD) Treatment Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2015-2020)
Table 31. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2015-2020) (K Pcs)
Table 32. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2015-2020)
Table 33. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2015-2020)
Table 35. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 36. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Table 37. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 38. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Table 39. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2015-2020)
Table 41. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2015-2020)
Table 43. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Table 45. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Table 55. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2015-2020)
Table 59. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Table 61. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Table 71. ArmaGen Inc Corporation Information
Table 72. ArmaGen Inc Description and Major Businesses
Table 73. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. ArmaGen Inc Product
Table 75. ArmaGen Inc Recent Development
Table 76. GlaxoSmithKline Plc Corporation Information
Table 77. GlaxoSmithKline Plc Description and Major Businesses
Table 78. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. GlaxoSmithKline Plc Product
Table 80. GlaxoSmithKline Plc Recent Development
Table 81. Recursion Pharmaceuticals Inc Corporation Information
Table 82. Recursion Pharmaceuticals Inc Description and Major Businesses
Table 83. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Recursion Pharmaceuticals Inc Product
Table 85. Recursion Pharmaceuticals Inc Recent Development
Table 86. RegenxBio Inc Corporation Information
Table 87. RegenxBio Inc Description and Major Businesses
Table 88. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. RegenxBio Inc Product
Table 90. RegenxBio Inc Recent Development
Table 91. Takeda Corporation Information
Table 92. Takeda Description and Major Businesses
Table 93. Takeda Metachromatic Leukodystrophy (MLD) Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. Takeda Product
Table 95. Takeda Recent Development
Table 96. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Regions (2021-2026) (K Pcs)
Table 97. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Regions (2021-2026)
Table 98. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 99. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share Forecast by Regions (2021-2026)
Table 100. North America: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 101. North America: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 102. Europe: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 103. Europe: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 104. Asia Pacific: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Region (2021-2026) (K Pcs)
Table 105. Asia Pacific: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Region (2021-2026) (US$ Million)
Table 106. Latin America: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 107. Latin America: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Middle East and Africa: Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 109. Middle East and Africa: Metachromatic Leukodystrophy (MLD) Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 111. Key Challenges
Table 112. Market Risks
Table 113. Main Points Interviewed from Key Metachromatic Leukodystrophy (MLD) Treatment Players
Table 114. Metachromatic Leukodystrophy (MLD) Treatment Customers List
Table 115. Metachromatic Leukodystrophy (MLD) Treatment Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Product Picture
Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type in 2020 & 2026
Figure 3. AGT-183 Product Picture
Figure 4. DUOC-01 Product Picture
Figure 5. GSK-2696274 Product Picture
Figure 6. Others Product Picture
Figure 7. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Metachromatic Leukodystrophy (MLD) Treatment Report Years Considered
Figure 12. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size 2015-2026 (US$ Million)
Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Sales 2015-2026 (K Pcs)
Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2015-2020)
Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region in 2019
Figure 17. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2015-2020)
Figure 18. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region in 2019
Figure 19. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Metachromatic Leukodystrophy (MLD) Treatment Revenue in 2019
Figure 21. Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2015-2020)
Figure 23. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type in 2019
Figure 24. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2015-2020)
Figure 25. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type in 2019
Figure 26. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Price Range (2015-2020)
Figure 27. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2015-2020)
Figure 28. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application in 2019
Figure 29. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2015-2020)
Figure 30. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application in 2019
Figure 31. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country in 2019
Figure 34. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country in 2019
Figure 35. U.S. Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2019
Figure 40. North America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2019
Figure 41. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country in 2019
Figure 44. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country in 2019
Figure 45. Germany Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2019
Figure 56. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2019
Figure 57. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region in 2019
Figure 60. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region in 2019
Figure 61. China Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2019
Figure 84. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2019
Figure 85. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country in 2019
Figure 88. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country in 2019
Figure 89. Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2019
Figure 96. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2019
Figure 97. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country in 2019
Figure 101. Turkey Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type in 2019
Figure 108. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application in 2019
Figure 109. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
グロボイド細胞白質ジストロフィー（GLD）治療の世界市場（～2026年） Market Analysis and Insights: Global Globoid Cell Leukodystrophy Treatment Market The global Globoid Cell Leukodystrophy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Globoid Cell Leukodystrophy Treatment S…- 代謝障害治療薬の世界市場（～2026年） Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes. Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the f…
- 多形性膠芽腫（GBM）治療の世界市場（～2026年） Glioblastoma is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and …
- 神経精神障害・治療の世界市場（～2026年） Neuropsychiatric disorder is a blanket medical term that encompasses a broad range of medical conditions that involve both neurology and psychiatry. Common neuropsychiatric disorders include seizures, attention deficits, cognitive deficits, palsies, uncontrolled anger, migraine headaches, addictions…
- 髄膜炎診断・治療の世界市場（～2026年） Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, vomiting, and an inability to tolerate …